Protecting the gains: analysis of HIV treatment and service delivery programme data and interventions implemented in 19 African countries during COVID-19.
COVID-19
differentiated care
retention
treatment
treatment interruption
viral suppression
Journal
Journal of the International AIDS Society
ISSN: 1758-2652
Titre abrégé: J Int AIDS Soc
Pays: Switzerland
ID NLM: 101478566
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
received:
16
03
2022
accepted:
20
10
2022
entrez:
24
11
2022
pubmed:
25
11
2022
medline:
26
11
2022
Statut:
ppublish
Résumé
The potential disruption in antiretroviral therapy (ART) services in Africa at the start of the COVID-19 pandemic raised concern for increased morbidity and mortality among people living with HIV (PLHIV). We describe HIV treatment trends before and during the pandemic and interventions implemented to mitigate COVID-19 impact among countries supported by the US Centers for Disease Control and Prevention (CDC) through the President's Emergency Plan for AIDS Relief (PEPFAR). We analysed quantitative and qualitative data reported by 10,387 PEPFAR-CDC-supported ART sites in 19 African countries between October 2019 and March 2021. Trends in PLHIV on ART, new ART initiations and treatment interruptions were assessed. Viral load coverage (testing of eligible PLHIV) and viral suppression were calculated at select time points. Qualitative data were analysed to summarize facility- and community-based interventions implemented to mitigate COVID-19. The total number of PLHIV on ART increased quarterly from October 2019 (n = 7,540,592) to March 2021 (n = 8,513,572). The adult population (≥15 years) on ART increased by 14.0% (7,005,959-7,983,793), while the paediatric population (<15 years) on ART declined by 2.6% (333,178-324,441). However, the number of new ART initiations dropped between March 2020 and June 2020 by 23.4% for adults and 26.1% for children, with more rapid recovery in adults than children from September 2020 onwards. Viral load coverage increased slightly from April 2020 to March 2021 (75-78%) and viral load suppression increased from October 2019 to March 2021 (91-94%) among adults and children combined. The most reported interventions included multi-month dispensing (MMD) of ART, community service delivery expansion, and technology and virtual platforms use for client engagement and site-level monitoring. MMD of ≥3 months increased from 52% in October 2019 to 78% of PLHIV ≥ age 15 on ART in March 2021. With an overall increase in the number of people on ART, HIV programmes proved to be resilient, mitigating the impact of COVID-19. However, the decline in the number of children on ART warrants urgent investigation and interventions to prevent further losses experienced during the COVID-19 pandemic and future public health emergencies.
Identifiants
pubmed: 36419346
doi: 10.1002/jia2.26033
pmc: PMC9684677
doi:
Substances chimiques
Anti-Retroviral Agents
0
Types de publication
Journal Article
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
e26033Subventions
Organisme : PEPFAR
Pays : United States
Informations de copyright
© 2022 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society.
Références
HIV Res Clin Pract. 2021 Aug;22(4):102-118
pubmed: 34514963
N Engl J Med. 2020 Jul 16;383(3):e11
pubmed: 32302075
Curr HIV/AIDS Rep. 2019 Aug;16(4):324-334
pubmed: 31230342
Pan Afr Med J. 2020 Nov 19;37:255
pubmed: 33598070
PLoS One. 2018 Dec 14;13(12):e0208814
pubmed: 30550574
J Int AIDS Soc. 2020 Apr;23(4):e25482
pubmed: 32239657
Clin Infect Dis. 2021 Oct 5;73(7):e2095-e2106
pubmed: 33095853
J Int AIDS Soc. 2020 Sep;23(9):e25622
pubmed: 32996705
J Med Virol. 2021 Mar;93(3):1687-1693
pubmed: 32949148
Clin Infect Dis. 2022 Jan 29;74(2):171-179
pubmed: 33993219
J Int AIDS Soc. 2020 Aug;23(8):e25587
pubmed: 32767707
J Int AIDS Soc. 2020 May;23(5):e25503
pubmed: 32378345
J Acquir Immune Defic Syndr. 2020 Nov 1;85(3):280-291
pubmed: 32665460
Arch Public Health. 2021 Jan 4;79(1):1
pubmed: 33390163
J Int AIDS Soc. 2021 Oct;24 Suppl 6:e25794
pubmed: 34713578
Trop Med Health. 2020 Apr 10;48:18
pubmed: 32288543
J Int AIDS Soc. 2018 Nov;21(11):e25207
pubmed: 30450699
J Int AIDS Soc. 2021 Jun;24(6):e25704
pubmed: 34105884
PLoS One. 2016 Dec 1;11(12):e0166444
pubmed: 27907084
Trop Med Int Health. 2017 Apr;22(4):375-387
pubmed: 28102610
Lancet Glob Health. 2021 May;9(5):e628-e638
pubmed: 33865471
Curr HIV/AIDS Rep. 2019 Dec;16(6):467-474
pubmed: 31776974
J Int AIDS Soc. 2017 Jul 21;20(Suppl 4):21650
pubmed: 28770594
J Virus Erad. 2018 Nov 15;4(Suppl 2):40-46
pubmed: 30515313
J Int AIDS Soc. 2020 Nov;23(11):e25640
pubmed: 33247517
Lancet HIV. 2020 Sep;7(9):e629-e640
pubmed: 32771089